Recent advances in biotechnologies have led to the development of multiplex genomic and proteomic analyses for clinical use. Nevertheless, guidelines are currently lacking to determine which molecular assays should be implemented in metastatic cancers. The 1(st) MAP conference was dedicated to exploring the use of genomics to better select therapies in the treatment of metastatic cancers. 16 consensus items were covered. While there was a consensus that new technologies like next-generation sequencing (NGS) of tumors and of ddPCR on circulating free DNA have convincing analytical validity, further work needs to be undertaken to establish both the clinical utility of liquid biopsies and the added clinical value of expanding from individual gene tests into large gene panels. Experts agreed that standardized bioinformatics methods for biological interpretation of genomic data are needed and that Precision Medicine trials should be stratified based on the level of evidence available for the genomic alterations identified.